114 related articles for article (PubMed ID: 35723064)
41. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
[TBL] [Abstract][Full Text] [Related]
42. Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis.
Mehta A; Vasudevan S
Cancer Treat Res Commun; 2021; 28():100398. PubMed ID: 34052672
[TBL] [Abstract][Full Text] [Related]
43. Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer.
Lahmadi M; Beddar L; Rouibah AL; Boumegoura A; Boufendi H; Temim A; Nini A; Sellam F; Satta D
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1063-1068. PubMed ID: 33906297
[TBL] [Abstract][Full Text] [Related]
44. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
Ghosh M; Mukhopadhyay M; Das C; Chatterjee S; Naskar BG
J Cancer Res Ther; 2021; 17(6):1389-1396. PubMed ID: 34916369
[TBL] [Abstract][Full Text] [Related]
45. Ado-trastuzumab emtansine in the treatment of lung adenocarcinoma with ERBB2 mutation: a case report and literature review.
Wang H; He Y; Zhao W; Tong Z
Anticancer Drugs; 2022 Sep; 33(8):773-777. PubMed ID: 35946510
[TBL] [Abstract][Full Text] [Related]
46. Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
Chu H; Zhong C; Xue G; Liang X; Wang J; Liu Y; Zhao S; Zhou Q; Bi J
Oncol Rep; 2013 Nov; 30(5):2311-5. PubMed ID: 24002698
[TBL] [Abstract][Full Text] [Related]
47. A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).
Ninomiya K; Hata T; Yoshioka H; Ohashi K; Bessho A; Hosokawa S; Ishikawa N; Yamasaki M; Shibayama T; Aoe K; Kozuki T; Harita S; Ueda Y; Murakami T; Fujimoto N; Yanai H; Toyooka S; Takata M; Hotta K; Kiura K;
Chest; 2019 Aug; 156(2):357-366. PubMed ID: 31072612
[TBL] [Abstract][Full Text] [Related]
48. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
49. The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma.
Kirchner M; Kluck K; Brandt R; Volckmar AL; Penzel R; Kazdal D; Endris V; Neumann O; Seker-Cin H; Goldschmid H; Glade J; Allgäuer M; Kriegsmann M; Winter H; Muley T; Perner S; Frost N; Reck M; Fröhling S; Schirmacher P; Thomas M; Budczies J; Christopoulos P; Stenzinger A
ESMO Open; 2021 Oct; 6(5):100253. PubMed ID: 34487971
[TBL] [Abstract][Full Text] [Related]
50. Mutation Spectrum of
Mao L; Zhao W; Li X; Zhang S; Zhou C; Zhou D; Ou X; Xu Y; Tang Y; Ou X; Hu C; Ding X; Luo P; Yu S
Pathol Oncol Res; 2021; 27():602726. PubMed ID: 34257561
[TBL] [Abstract][Full Text] [Related]
51. Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China.
Zhou Y; Yang Y; Yang C; Chen Y; Yang C; Du Y; Zhao G; Guo Y; Ye L; Huang Y
Oncotarget; 2017 Feb; 8(9):15023-15033. PubMed ID: 28107191
[TBL] [Abstract][Full Text] [Related]
52. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
[TBL] [Abstract][Full Text] [Related]
53. [Detection of epidermal growth factor receptor gene mutations in advanced non-small cell lung cancer].
Wang S; Han XH; Li JL; Hu XS; Wang XY; Gui L; Zhao LD; Sun Y; Shi YK
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):530-3. PubMed ID: 23157744
[TBL] [Abstract][Full Text] [Related]
54. Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy.
Tian P; Zeng H; Ji L; Ding Z; Ren L; Gao W; Fan Z; Li L; Le X; Li P; Zhang M; Xia X; Zhang J; Li Y; Li W
Lung Cancer; 2021 Oct; 160():50-58. PubMed ID: 34403912
[TBL] [Abstract][Full Text] [Related]
55. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
[TBL] [Abstract][Full Text] [Related]
56. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL
Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455
[TBL] [Abstract][Full Text] [Related]
57. [Correlation between EGFR gene mutation and high copy number and their association with the clinicopathological features in Chinese patients with non-small cell lung cancer].
Li Z; Zhang LJ; Wang WP; Guo K; Shao JY; Rong TH
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):666-70. PubMed ID: 22340046
[TBL] [Abstract][Full Text] [Related]
58. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
Barlesi F; Mazieres J; Merlio JP; Debieuvre D; Mosser J; Lena H; Ouafik L; Besse B; Rouquette I; Westeel V; Escande F; Monnet I; Lemoine A; Veillon R; Blons H; Audigier-Valette C; Bringuier PP; Lamy R; Beau-Faller M; Pujol JL; Sabourin JC; Penault-Llorca F; Denis MG; Lantuejoul S; Morin F; Tran Q; Missy P; Langlais A; Milleron B; Cadranel J; Soria JC; Zalcman G;
Lancet; 2016 Apr; 387(10026):1415-1426. PubMed ID: 26777916
[TBL] [Abstract][Full Text] [Related]
59. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
Bai H; Mao L; Wang HS; Zhao J; Yang L; An TT; Wang X; Duan CJ; Wu NM; Guo ZQ; Liu YX; Liu HN; Wang YY; Wang J
J Clin Oncol; 2009 Jun; 27(16):2653-9. PubMed ID: 19414683
[TBL] [Abstract][Full Text] [Related]
60. HER2 mutations in Chinese patients with non-small cell lung cancer.
Song Z; Yu X; Shi Z; Zhao J; Zhang Y
Oncotarget; 2016 Nov; 7(47):78152-78158. PubMed ID: 27825109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
